- Home
- BJDX vs XXII Comparison
BJDX vs XXII Comparison
Compare BJDX & XXII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BJDX
- XXII
- Stock Information
- Founded
- BJDX 2015
- XXII 1998
- Country
- BJDX United States
- XXII United States
- Employees
- BJDX N/A
- XXII N/A
- Industry
- BJDX Medical Specialities
- XXII Medicinal Chemicals and Botanical Products
- Sector
- BJDX Health Care
- XXII Health Care
- Exchange
- BJDX Nasdaq
- XXII Nasdaq
- Market Cap
- BJDX 2.2M
- XXII 2.1M
- IPO Year
- BJDX 2021
- XXII N/A
- Fundamental
- Price
- BJDX $1.67
- XXII $0.80
- Analyst Decision
- BJDX
- XXII
- Analyst Count
- BJDX 0
- XXII 0
- Target Price
- BJDX N/A
- XXII N/A
- AVG Volume (30 Days)
- BJDX 3.4M
- XXII 1.6M
- Earning Date
- BJDX 05-14-2025
- XXII 05-14-2025
- Dividend Yield
- BJDX N/A
- XXII N/A
- EPS Growth
- BJDX N/A
- XXII N/A
- EPS
- BJDX N/A
- XXII N/A
- Revenue
- BJDX N/A
- XXII $24,382,000.00
- Revenue This Year
- BJDX N/A
- XXII $19.23
- Revenue Next Year
- BJDX $55.56
- XXII $81.05
- P/E Ratio
- BJDX N/A
- XXII N/A
- Revenue Growth
- BJDX N/A
- XXII N/A
- 52 Week Low
- BJDX $1.48
- XXII $0.70
- 52 Week High
- BJDX $316.80
- XXII $265.95
- Technical
- Relative Strength Index (RSI)
- BJDX 38.27
- XXII 26.33
- Support Level
- BJDX $1.46
- XXII $0.70
- Resistance Level
- BJDX $3.60
- XXII $0.83
- Average True Range (ATR)
- BJDX 0.63
- XXII 0.21
- MACD
- BJDX -0.13
- XXII 0.05
- Stochastic Oscillator
- BJDX 2.40
- XXII 5.92
About BJDX Bluejay Diagnostics Inc.
Bluejay Diagnostics Inc is a medical diagnostics company. It is developing rapid tests using whole blood using its Symphony technology platform to improve patient outcomes in critical care settings. The company's first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings and is a clinically established inflammatory biomarker for the assessment of the severity of infection and inflammation across many disease indications, including sepsis.
About XXII 22nd Century Group Inc.
22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.